Comparative Analysis of Vitamin D, Folic Acid, and Antioxidant Minerals in Various Stages of Lung Cancer.

Background: Lung cancer continues to be one of the most common causes of death due to lung malignancies globally. Emerging research suggests that vitamins and trace minerals, particularly antioxidants, may play a role in cancer progression and treatment outcomes. This study conducts a comparative analysis of vitamin D, folic acid, and trace minerals (copper, zinc, and magnesium) in various stages of lung cancer patients.

Methods: A cross-sectional study was conducted with 160 lung cancer patients, categorized into four stages (Stage 1 to Stage 4). Standardized biochemical assays, such as chemiluminescent immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and atomic absorption spectroscopy (AAS), were used to measure the levels of vitamin D, folic acid, copper (Cu), zinc (Zn), and magnesium (Mg) in the blood. The nutrient levels were compared across stages to investigate any significant variations.

Results: Vitamin D levels decreased significantly as lung cancer progressed, with Stage 1 showing the highest mean level (33 ng/mL) and Stage 4 the lowest (8 ng/mL). Folic acid levels fluctuated, showing a general decrease in the advanced stages, with some variations in the intermediate stages. Copper levels showed individual variability without a consistent trend across stages. Zinc levels were higher in early-stage patients and decreased as cancer progressed. Magnesium levels remained relatively stable across all stages.

Conclusion: This comparative analysis highlights the potential significance of monitoring vitamin D, folic acid, and trace minerals in lung cancer patients across different stages. The results suggest that these nutrients may play a role in the progression of lung cancer and could serve as biomarkers for disease staging.